Detailed Narrative
Record Q4 and FY25 Performance
RadNet achieved its strongest quarter ever in Q4 FY25, reporting record revenue of $547.7 million, a 14.8% increase year-over-year, and record adjusted EBITDA of $87.7 million, up 16.9% year-over-year. The full year 2025 results met or exceeded original guidance levels for Imaging Center revenue, adjusted EBITDA, and free cash flow, demonstrating robust operational execution and market demand.
Advanced Imaging Growth and Modality Mix Shift
The company experienced significant growth in advanced imaging, with aggregate procedural volume increasing 14.1% and same-center volume growing 9.6% in Q4 FY25. Advanced imaging, including MRI, CT, and PET/CT, now accounts for 28.6% of RadNet's procedural volume, a 178 basis point increase from the prior year. This shift towards higher-acuity procedures is a key driver of revenue, margin, and overall profitability, supported by technological advancements and capital investments in equipment.
Strategic Investments and Expansion
In 2025, RadNet opened 7 de novo facilities to address backlogs and expand capacity, and expanded several joint venture partnerships. The company also made strategic acquisitions, including imaging facilities in California, New York, and Maryland. Post-year-end, RadNet further expanded its footprint by acquiring 13 centers in Southwest Florida, 6 facilities in Indiana, and a single center in Virginia, demonstrating a 'land and expand' strategy in new markets.
Gleamer Acquisition and AI Strategy
RadNet announced the acquisition of Paris-based Gleamer for up to EUR 230 million, integrating its AI solutions into DeepHealth. This acquisition positions DeepHealth as the largest provider of radiology clinical AI solutions worldwide, bringing over 700 customer contracts, 25+ clinical indications, and an expected $30 million in ARR for 2026. The strategy aims to leverage AI to enhance workflow efficiency, productivity, and accuracy in radiology, addressing labor shortages and improving patient outcomes.
Digital Health Growth and ARR
The Digital Health segment showed strong growth, with Q4 FY25 revenue increasing 48.2% to $27.9 million and full-year revenue reaching $92.7 million. The segment's Annual Recurring Revenue (ARR) stood at $75.4 million at year-end 2025 and is projected to approach $140 million by the end of 2026, driven by sales of the DeepHealth portfolio and Gleamer's contribution. RadNet anticipates a minimum of four FDA clearances for its AI solutions in 2026 across various clinical areas.
Financial Strength and Leverage Management
RadNet maintained a strong financial position at the end of 2025, with a cash balance of $776 million and a net debt to adjusted EBITDA leverage ratio of approximately 1.0x. Despite recent acquisitions in early 2026, the company remains committed to operating with low leverage, projecting a pro forma net debt to adjusted EBITDA ratio between 1.6x and 1.8x, reflecting disciplined capital allocation.